PMID: 8610173Apr 2, 1996Paper

Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2

Proceedings of the National Academy of Sciences of the United States of America
K SomasundaramB Thimmapaya

Abstract

Adenovirus E1A 243-amino acid protein can repress a variety of enhancer -linked viral and cellular promoters. This repression is presumed to be mediated by its interaction with and sequestration of p3OO, a transcriptional coactivator. Type IV 72-kDa collagenase is one of the matrix metalloproteases that has been implicated in differentiation, development, angiogenesis, and tumor metastasis. We show here that the cell type-specific transcription factor AP-2 is an important transcription factor for the activation of the type IV 72-kDa collagenase promoter and that adenovirus E1A 243-amino acid protein represses this promoter by targeting AP-2. Glutathione S-transferase-affinity chromatography studies show that the E1A protein interacts with the DNA binding/dimerization region of AP-2 and that the N-terminal amino acids of E1A protein are required for this interaction. Further, E1A deletion mutants which do not bind to p3OO can repress this collagenase promoter as efficiently as the wildtype E1A protein. Because the AP-2 element is present in a variety of viral and cellular enhancers which are repressed by E1A, these studies suggest that E1A protein can repress cellular and viral promoter/enhancers by forming a complex with cellul...Continue Reading

Citations

Jun 14, 2002·Molecular and Cellular Endocrinology·You-Hong Cheng, Stuart Handwerger
Mar 15, 2000·Molecular and Cellular Endocrinology·B D RichardsonS Handwerger
Oct 31, 2001·Trends in Cell Biology·R J Akhurst, R Derynck
Jan 1, 1997·Nature Genetics·Y X ZengW S el-Deiry
Feb 21, 1998·Nucleic Acids Research·J S Mymryk
Jan 20, 2006·Genome Biology·Dawid EckertHubert Schorle
Jun 21, 2001·Biochemical and Biophysical Research Communications·K R LaderouteR S Johnson
Nov 13, 1998·Proceedings of the National Academy of Sciences of the United States of America·T NottoliT Williams
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·T C LeeE B Ziff
Mar 3, 2007·International Journal of Cancer. Journal International Du Cancer·Johanna M Pellikainen, Veli-Matti Kosma
Nov 10, 2010·Wiley Interdisciplinary Reviews. Systems Biology and Medicine·Horng D OuClodagh C O'Shea
Mar 14, 2009·The Journal of General Virology·Anna BasileKamel Khalili
Dec 22, 1999·Oncogene·K SomasundaramW S el-Deiry
Mar 15, 2006·The Journal of Biological Chemistry·Narendra WajapeyeeKumaravel Somasundaram
Dec 11, 2019·FEBS Letters·Wing Hang Ip, Thomas Dobner
Aug 15, 1997·The Journal of Biological Chemistry·N H BishopricK A Webster
Mar 18, 2003·The Journal of Biological Chemistry·Sanjeev DasKumaravel Somasundaram
Nov 11, 2003·Orthodontics & Craniofacial Research·J C Minarcik, J A Golden
Oct 25, 2003·Journal of Neuropathology and Experimental Neurology·Bernd O EvertUllrich Wüllner
Aug 26, 1998·Molecular and Cellular Biology·E VealG Gill
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Johanna M PellikainenVeli-Matti Kosma

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.